Itoi, Keiichi C (3-6 months) CRF-Venus, B6-Crh/venus KI CRF-Venus, B6-Crh/venus KI RBRC06519 Necessary documents for ordering:<ol><li>Approval form (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_6.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_d.docx">English</A>)</li><li>Order form (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_4.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_b.docx">English</A>)</li><li>Category I MTA: MTA for distribution with RIKEN BRC (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_5.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_c.docx">English</A>)</li><li>The RECIPIENT of BIOLOGICAL RESOURCE must obtain a prior written consent on use of it from the DEVELOPER of the Venus using Approval form (<a HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/Form_V.docx">Form V (English)</a>) (Lab Contact: Laboratory for Cell Function Dynamics, RIKEN CBS: mta-cfds@ml.riken.jp).</li><li>Acceptance of responsibility for living modified organism (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_7.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_g.docx">English</A>)</li></ol> Developed by Keiichi Itoi, Graduate School of Information Sciences, Tohoku University and Kenji Sakimura, Brain Research Institute, Niigata University in 2011. RENKA ES cells were used to generate the mutant mice. 条件を付加する。<br>研究成果の公表にあたって寄託者の指定する文献を引用する。Endocrinology. 2014 en20141182.<br>利用者は提供承諾書を用いて、事前に寄託者の承諾を得る。利用者はApproval form (form V)を用いて、事前にVenusの開発者の許可を得る(連絡先:Laboratory for Cell Function Dynamics, RIKEN CBS: mta-cfds@ml.riken.jp) Heterozygote x Wild-type [C57BL/6NJcl] Heterozygote x Wild-type [C57BL/6NJcl] C57BL/6N-Crh<tm1(venus)Ksak> C57BL/6N-Crh<tm1(venus)Ksak> 東北大学大学院情報科学研究科・井樋慶一先生、新潟大学脳研究所・崎村健司先生(2011)。RENKA ES細胞を用いて作出。 Crh (CRF, Corticotropin releasing factor) gene venus knock-in mice. A Venus-frt-flanked PGK-neo cassette was inserted at the translation initiation site of the CRF gene. true In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the following literature(s) designated by the DEPOSITOR is requested. Endocrinology. 2014 en20141182.Prior to requesting the BIOLOGICAL RESOURCE, the RECIPIENT must obtain approval from the DEPOSITOR using the Approval Form (form D). The RECIPIENT of BIOLOGICAL RESOURCE must obtain a prior written consent on use of it from the DEVELOPER of the Venus using Approval form (form V) (Lab Contact: Laboratory for Cell Function Dynamics, RIKEN CBS: mta-cfds@ml.riken.jp). C(3〜6か月) 井樋 慶一 FLP/frt system RENKA [C57BL/6NCrlCrlj] Fluorescent Proteins/lacZ System A. coerulescens Venus mutant GFP cDNA, yeast FRT (flipase recombination target) sites, mouse phosphoglycerate kinase promoter (PGK promoter), phage T7 gb2 promoter(synthetic), E. coli Neomycin resistance gene, mouse Crh genomic DNA Crh (CRF, Corticotropin releasing factor) 遺伝子のvenusノックインマウス。エクソン2の開始コドンATGにVenus-frt-flanked-PGK-neoカセットが挿入されている。視床下部、分界条床核などのCRF発現細胞にてvenus由来の蛍光を示す。